Unknown

Dataset Information

0

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.


ABSTRACT: We explored the duration of immune responses and the effect of a late third HIV-modified vaccinia virus Ankara (MVA) boost in HIV-DNA primed and HIV-MVA boosted Tanzanian volunteers. Twenty volunteers who had previously received three HIV-DNA and two HIV-MVA immunizations were given a third HIV-MVA immunization 3 years after the second HIV-MVA boost. At the time of the third HIV-MVA, 90% of the vaccinees had antibodies to HIV-1 subtype C gp140 (median titer 200) and 85% to subtype B gp160 (median titer 100). The majority of vaccinees had detectable antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies, 70% against CRF01_AE virus-infected cells (median titer 239) and 84% against CRF01_AE gp120-coated cells (median titer 499). A high proportion (74%) of vaccinees had IFN-? ELISpot responses, 63% to Gag and 42% to Env, 3 years after the second HIV-MVA boost. After the third HIV-MVA, there was an increase in Env-binding antibodies and ADCC-mediating antibodies relative to the response seen at the time of the third HIV-MVA vaccination, p?

SUBMITTER: Joachim A 

PROVIDER: S-EPMC5564012 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

Joachim Agricola A   Munseri Patricia J PJ   Nilsson Charlotta C   Bakari Muhammad M   Aboud Said S   Lyamuya Eligius F EF   Tecleab Teghesti T   Liakina Valentina V   Scarlatti Gabriella G   Robb Merlin L ML   Earl Patricia L PL   Moss Bernard B   Wahren Britta B   Mhalu Fred F   Ferrari Guido G   Sandstrom Eric E   Biberfeld Gunnel G  

AIDS research and human retroviruses 20170127 8


We explored the duration of immune responses and the effect of a late third HIV-modified vaccinia virus Ankara (MVA) boost in HIV-DNA primed and HIV-MVA boosted Tanzanian volunteers. Twenty volunteers who had previously received three HIV-DNA and two HIV-MVA immunizations were given a third HIV-MVA immunization 3 years after the second HIV-MVA boost. At the time of the third HIV-MVA, 90% of the vaccinees had antibodies to HIV-1 subtype C gp140 (median titer 200) and 85% to subtype B gp160 (media  ...[more]

Similar Datasets

| S-EPMC3938943 | biostudies-literature
| S-EPMC3592345 | biostudies-literature
| S-EPMC4072895 | biostudies-literature
| S-EPMC5571275 | biostudies-literature
| S-EPMC6600201 | biostudies-literature
| S-EPMC6450106 | biostudies-literature
| S-EPMC2863849 | biostudies-literature
| S-EPMC4349667 | biostudies-literature
| S-EPMC7115540 | biostudies-literature
| S-EPMC7111619 | biostudies-literature